Turku PET Centre, University of Turku, Turku, Finland.
Turku Brain and Mind Center, Institute of Clinical Medicine, University of Turku, Finland.
J Alzheimers Dis. 2018;63(1):79-85. doi: 10.3233/JAD-170569.
Our aim was to assess whether in vivo11C-PIB negative memory-impaired subjects may nonetheless exhibit brain Alzheimer's disease (AD) pathology. We re-evaluated the PET images and systematically characterized the postmortem neuropathology of six individuals who had undergone clinically indicated amyloid PET. The single case with negligible amyloid-β (Aβ) pathology had Lewy body disease, where concomitant AD changes are often seen. Further, the subject's plaques were predominantly diffuse. The predictive value of a negative 11C-PIB scan appears to be good, even in memory-impaired populations. Our results suggest that considerable neuritic Aβ plaque pathology in the absence of specific/cortical 11C-PIB binding upon PET is unlikely.
我们的目的是评估体内 11C-PIB 阴性的记忆障碍患者是否仍然存在脑阿尔茨海默病 (AD) 病理学。我们重新评估了六名接受临床指示性淀粉样蛋白 PET 检查的患者的 PET 图像,并系统地描述了他们的死后神经病理学特征。唯一一例淀粉样蛋白-β (Aβ) 病理学可忽略不计的患者患有路易体病,其中经常同时出现 AD 改变。此外,该患者的斑块主要为弥漫性。即使在记忆障碍人群中,11C-PIB 扫描阴性的预测价值似乎也很好。我们的结果表明,在 PET 上不存在特定/皮质 11C-PIB 结合的情况下,存在大量神经原纤维 Aβ 斑块病理学的可能性不大。